Discovery, Synthesis, SAR Development of a Series of N-4-(2,5-dioxopyrrolidin-1-yl)-phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu(4)) with Oral Efficacy in an anti-Parkinsonian Animal Model

Ítems similars

• Discovery, Synthesis, and Structure Activity Relationship Development of a Series of N-(4-acetamido)phenylpicolinamides as Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 (mGlu(4)) with CNS Exposure in Rats
  per: Engers, Darren W., et al.
  Publicat: (2011)
• Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu(2/4) Heteromers
  per: Niswender, Colleen M., et al.
  Publicat: (2016)
• Discovery of VU2957 (Valiglurax): An mGlu(4) Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson’s Disease
  per: Panarese, Joseph D., et al.
  Publicat: (2018)
• Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 1. SAR of modifications to the central aryl core
  per: Garcia-Barrantes, Pedro M., et al.
  Publicat: (2015)
• Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy
  per: Gogliotti, Rocco D., et al.
  Publicat: (2016)